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INTRODUCTION
Dermatofibroma (DF) is a common benign fibro-
histiocytic tumor that is histologically characterized
by proliferating fibroblasts, collagen, capillaries, and
histiocytes and is accompanied by seborrhoeic kera-
tosis-like epidermal hyperplasia with hyperpigmen-
tation of the basal layer (1). Dermatofibrosarcoma
protuberans (DFSP) is a slowly growing dermal
neoplasm of intermediate malignancy that is his-
tologically composed of spindle cells with a stori-
form pattern and is often characterized by an at-
tenuated or ulcerated epidermis in the absence of
hyperpigmentation (1). Despite these characteris-
tic features, it is sometimes difficult to distinguish
between DF and DFSP. Although CD34 and factor
XIII have been widely used to distinguish DF from
DFSP, these markers often show an overlap and
lack of specificity (2). Cytogenetically, DFSP is char-
acterized by a reciprocal translocation, t (17 ; 22)
(q22 ; q13), and a supernumerary ring chromo-
some derived from this translocation, and the fusion
transcripts of COL1A1 and PDGFB genes were de-
tected in DFSP as a reliable and useful diagnostic
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marker for DFSP (3). However, COL1A1-PDGFB
fusions have not been detected in around 8% of the
lesions of DFSP (4).
Fibroblast growth factors (FGFs) and their re-
ceptors (FGFRs) control a wide range of biological
functions including the regulation of cellular prolif-
eration, survival, migration, and differentiation (5).
The FGF family comprises 18 ligands that exert
their actions through 4 highly conserved transmem-
brane tyrosine kinase receptors (FGFR1, FGFR2,
FGFR3, and FGFR4) (5). Although overexpression
of FGFR2 has been reported in the epidermal and
dermal regions of DF (6), the involvement of other
FGFRs in DF and all 4 FGFRs in DFSP has not yet
been examined.
Among FGFRs, the activating mutations of
FGFR3 have been reported to be involved in sev-
eral cancers including bladder carcinoma (7), cer-
vix carcinoma (7), oral squamous cell carcinoma
(8), and colorectal carcinoma (9). The activation of
FGFR3 signaling pathways in benign epidermal le-
sions, e.g., seborrhoeic keratosis (10, 11) and epi-
dermal nevus (12), has been described previously.
We also reported the activation of FGFR3 in sebor-
rhoeic keratosis (13) and acanthosis nigricans (14).
In addition, the transcriptional factor forkhead box
N1 (FOXN1) has been identified as a downstream
target of FGFR3 (15). The activation of FGFR3
induces the transcription of FOXN1, and FOXN1
also induces the transcription of FGFR3, indicat-
ing a positive feedback loop between FGFR3 and
FOXN1 (15).
In this study, we first examined the presence of
the fusion transcripts of COL1A1-PDGFB genes in
DFSP to confirm the histological diagnosis. Next,
in order to understand the involvement of FGFRs
in the pathogenesis of seborrhoeic keratosis-like
epidermal changes in DF and the tumor lesions of
DF and DFSP, we investigated the expression of all
4 FGFRs (FGFR1, FGFR2, FGFR3, and FGFR4),
some of their ligands (FGF1, FGF2, and FGF9), and




Specimens of 20 DF, 6 DFSP, 11 seborrhoeic
keratosis, and 20 normal skins were obtained with
informed consent from patients who underwent re-
section at the Tokushima University Hospital.
RT-PCR analysis to detect the fusion transcripts of
COL1A1-PDGFB genes
Tissue samples were from 6 cases of DFSP,
which were diagnosed on the basis of histological
findings and were positive for CD34 staining. Total
RNA was extracted from frozen tissues using the
RNeasy Mini Kit (Qiagen, Hilden, Germany), and
reverse transcription was performed with random
hexamers using the Omniscript RT kit (Qiagen). To
detect the fusion transcripts of COL1A1-PDGFB
genes, PCR was performed using 16 kinds of
COL1A1 forward primers and a specific PDGFB
reverse primer according to the method of Wang
et al (17). If obvious PCR products were obtained,
these products were directly sequenced as previ-
ously reported (13).
Immunohistochemistry
An immunohistochemical investigation was per-
formed as described previously (13). Sections were
incubated with primary antibodies : a rabbit poly-
clonal anti-FGFR1 antibody (diluted 1 : 50, clone
sc-405 ; Santa Cruz Biotechnology, Santa Cruz,
CA, U.S.A.), a rabbit polyclonal anti-FGFR2 anti-
body (diluted 1 : 200, clone sc-20735 ; Santa Cruz
Biotechnology, Santa Cruz, CA, U.S.A.), a mouse
monoclonal anti-FGFR3 antibody (diluted 1 : 25,
clone sc-13121 ; Santa Cruz Biotechnology, Santa
Cruz, CA, U.S.A.), a rabbit polyclonal anti-FGFR4
antibody (diluted 1 : 100, clone sc-124 ; Santa Cruz
Biotechnology, Santa Cruz, CA, U.S.A.), a goat poly-
clonal anti-FGF1 antibody (diluted 1 : 200, clone sc-
1884 ; Santa Cruz Biotechnology, Santa Cruz, CA,
U.S.A.), a rabbit polyclonal anti-FGF2 antibody (di-
luted 1 : 200, clone sc-79 ; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, U.S.A.), a mouse monoclonal
anti-FGF9 antibody (diluted 1 : 200, clone sc-8413 ;
Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.),
and a rabbit polyclonal anti-FOXN1 antibody (di-
luted 1 : 200, clone sc-30195 ; Santa Cruz Biotech-
nology, Santa Cruz, CA, U.S.A.) at 4overnight.
After slides were washed in PBS, FGFR1, FGFR2,
FGFR3, FGFR4, FGF2, FGF9, and FOXN1 were de-
tected with the Envision+ kit (Dako, Kyoto, Japan)
for 30 min. After further washing, immunoperoxi-
dase staining was developed using a diamino-
benzidine chromogen (Dako) followed by counter-
staining with the Mayer’s haematoxylin. After slides
were washed in PBS, FGF1 was detected with an
anti-goat streptavidin-biotin kit (Histofine SAB-
PO (R) ; Nichirei, Tokyo, Japan), according to the
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manufacturer’s instructions. Sections were incu-
bated in diaminobenzidine tetrahydrochloride until
the desired staining was attained and counterstained
with Mayer’s haematoxylin. Immunoreactivity for
FGFR1 in breast cancer, FGFR2 in the normal epi-
dermis of skin, FGFR3 in the internal root sheath
of hair follicles, FGFR4 and FGF1 in pancreatic can-
cer, FGF2 in colon cancer, FGF9 in lung cancer,
and FOXN1 in seborrhoeic keratosis were regarded
as positive controls, respectively. For the evaluation
of the grade of immunoreactivity, the following
scale was used : (-) negative (5% positive cells) ;
(+) weakly positive (5-24% positive cells) ; (++) mod-
erately positive (25-50% positive cells) ; and (+++)
strongly positive (50% positive cells). Immuno-
histochemical analysis was performed by two doc-
tors in a blind fashion, without knowledge of clini-
copathological information.
Statistical analysis
The χ2 test was used for examining the differ-
ence between DF and DFSP in immunoreactivity
for each of FGFR2, FGFR3, FGFR4, FGF2, and
FOXN1.
RESULTS
RT-PCR analysis to detect the fusion transcripts of
COL1A1-PDGFB genes
The characteristics of 6 patients with DFSP are
summarized in Table 1. The fusion transcripts of
COL1A1-PDGFB genes were detected in all cases
of DFSP, whose histological diagnosis was con-
firmed. RT-PCR analysis followed by sequence
analysis revealed that each end of exons 25, 44, 47,
34, 2, and 17 of the COL1A1 gene were fused with
the start of exon 2 of the PDGFB gene in each
case of DFSP, respectively. For example, the end
of exon 17 of the COL1A1 gene was fused with the
start of exon 2 of the PDGFB gene in a sample
from patient 6 (Figure 1).
Immunohistochemical analysis
Results of the immunohistochemistry analysis for
FGFR2 and FGFR3 in epidermal regions of DF and
DFSP are summarized in Table 2. All normal epi-
dermis samples tested negative (-) to weakly posi-
tive (+) in the suprabasal to granular layer (data
not shown). All cases of DF were moderately (++)
to strongly positive (+++), and the expression of
FGFR3 was shown to be strong in the basal layer ;
however, all cases of DFSP were negative to weakly
positive (+) (Figure 2). The difference in FGFR3
expression between DF and DFSP was significant
(Table 2). All normal epidermis samples were
weakly positive (+) for FGFR2 (data not shown).
Although 17 of 20 cases (85%) of DF were moder-
ately positive (++) for FGFR2, the difference in
FGFR2 expression between DF and DFSP was not
significant (Table 2). Expression patterns of FGFR1
and FGFR4 in epidermal regions of DF and DFSP
were similar to the normal epidermis (data not
shown).
A summary of the expression of FOXN1 as a
downstream target of FGFR3 in the epidermal re-
gions of DF and DFSP, and seborrhoeic keratosis
is shown in Table 2. Almost all normal skin sam-
ples were negative, and FOXN1 was localized to
the nucleus in normal epidermis samples (data not
shown). Seventeen of 20 cases (85%) of DF were
moderately (++) to strongly positive (+++), and the
expression of FOXN1 was shown to be strong in
the basal layer (Figure 3). All cases of DFSP were
negative (-) (Figure 3). Nine of 11 cases (82%) of
seborrhoeic keratosis were strongly positive (+++),
and the expression of FOXN1 was shown to be
strong in the suprabasal to granular layer (Figure
3). The difference in FOXN1 expression between
Table 1. Summary of 6 patients with DFSP
Patients Age/sex Sites CD34 COL1A1 breakpoints
1 38/M Upper arm + Exon 25
2 25/F Abdomen + Exon 44
3 84/F Chest + Exon 47
4 29/M Abdomen + Exon 34
5 43/M Subclavicular + Exon 2
6 47/F Abdomen + Exon 17
Figure 1. DNA sequencing. A fusion transcript of the end of
exon 17 in the COL1A1 gene bound with the start of exon 2 in
the PDGFB gene was identified.
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DFSP and DF was significant (Table 2).
Results of the analysis for FGFR4 in the tumor
lesions of DF and DFSP are shown in Table 3. All
normal dermis samples were negative (-). Sixteen
of 20 cases (80%) of DF were moderately (++) to
strongly positive (+++), while all cases of DFSP
were negative (-) to weakly positive (+) (Figure 4).
The difference in FGFR4 expression between DF
and DFSP was significant (Table 3). On the other
hand, expressions for FGFR1, FGFR2, and FGFR3
were negative (-) in the tumor lesions of DF and
DFSP as well as normal dermis samples (data not
shown).
Results of the analysis for FGF2 in the tumor le-
sions of DF and DFSP are shown in Table 3. All
normal dermis samples were negative (-). All cases
of DF were moderately (++) to strongly positive
(+++), while 5 of 6 cases (83%) of DFSP were nega-
tive (-) to weakly positive (+) (Figure 5). The dif-
ference in FGF2 expression between DF and DFSP
was significant (Table 3). Expressions of FGF1
and FGF9 were negative (-) in the epidermal and
dermal regions of DF and DFSP as well as normal
skin, and expression patterns of FGF2 in the epider-
mal regions of DF and DFSP were similar to nor-
mal epidermis samples (data not shown).
Table 2. Summary of protein expression in the epidermal regions
Lesions
FGFR3 expression FGFR2 expression FOXN1 expression
Sum
(-) (+) (++) (+++) (-) (+) (++) (+++) (-) (+) (++) (+++)
the epidermal regions of DF 0 0 5 15 0 3 17 0 0 3 2 15 20
the epidermal regions of DFSP 4 2 0 0 0 4 2 0 6 0 0 0 6
Seborrhoeic keratosis - - - - - - - - 0 0 2 9 11
In FGFR3 expression, DF vs DFSP : P0.000001 ; in FOXN1 expression, DF vs DFSP : P0.000001.
The differences between DF and DFSP in FGFR2 expression were not statistically significant (P0.05).
(-),5% positive cells ; (+), 5 -24% ; (++), 25-50% ; (+++),50%.
Figure 2. Immunohistochemical staining for FGFR3. Typical images of FGFR3 staining in the internal root sheath of a hair follicle
(a), dermatofibroma (DF) (b), and dermatofibrosarcoma protuberans (DFSP) (c). (a) Cytoplasm and cell membrane of the internal
root sheath of hair follicles were regarded as a positive control. (b) Strongly positive (+++) staining for FGFR3 in DF. FGFR3 ex-
pression was strong in the basal layer. (c) Negative (-) staining for FGFR3 in DFSP.
Figure 3. Immunohistochemical staining for FOXN1. Typical images of FOXN1 staining in seborrhoeic keratosis (a), DF (b), and
DFSP (c). (a) Seborrhoeic keratosis was regarded as a positive control. FOXN1 expression was strong in the suprabasal to granular
layer. (b) Strongly positive (+++) staining for FOXN1 in DF. FOXN1 expression was strong in the basal layer. (c) Negative (-) stain-
ing for FOXN1 in DFSP.
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DISCUSSION
Transmembrane tyrosine kinase receptors of
FGFRs consist of FGFR1, FGFR2, FGFR3, and
FGFR4, and the activation of each of the FGFR
signaling pathways has been reported to be ob-
served in several kinds of cancers (18). Among
them, the activation of FGFR3 signaling pathways
in benign epidermal lesions including seborrhoeic
keratosis (10, 11, 13), epidermal nevus (12), and
acanthosis nigricans (14) has been reported. In this
study, the epidermal regions of DF were moder-
ately (++) to strongly positive (+++), and the expres-
sion of FGFR3 was shown to be strong in the basal
layer (Figure 2). On the other hand, no expression
of FGFR3 was seen in the epidermal regions of
DFSP. The epidermal regions of DF were similar to
seborrhoeic keratosis both in terms of histological
features and the molecular characteristics of over-
expression of FGFR3. We believe that overexpres-
sion of FGFR3 may contribute to the development
of epidermal changes in DF.
In previous studies, the roles of FGFR2 (6) and
EGF/EGFR (19) were proposed for the induction of
epidermal hyperplasia in the epidermal regions of
DF. We also showed that the expression of FGFR2
was moderately positive (++) in 17 of 20 epidermal
regions (85%) of DF. However, the difference in
FGFR2 expression between DF and DFSP was not
significant (Table 2). We suppose that FGFR3 may
Table 3. Summary of protein expression in the tumor lesions
Lesions
FGFR4 expression FGF2 expression
Sum
(-) (+) (++) (+++) (-) (+) (++) (+++)
the tumor lesions of DF 0 4 8 8 0 0 7 13 20
the tumor lesions of DFSP 2 4 0 0 2 3 1 0 6
In FGFR4 expression, DF vs DFSP : P0.00000001 ; in FGF2 expression, DF vs DFSP : P0.000000001. (-),5% positive cells ; (+),
5 -24% ; (++), 25-50% ; (+++),50%.
Figure 4. Immunohistochemical staining for FGFR4. Typical images of FGFR4 staining in DF(a), DFSP(b), and a pancreatic
cancer (c). (a) Strongly positive (+++) staining for FGFR4 in DF. (b) Negative (-) staining for FGFR4 in DFSP. (c) A pancreatic
cancer was regarded as a positive control.
Figure 5. Immunohistochemical staining for FGF2. Typical images of FGF2 staining in DF (a), DFSP (b), and a colon cancer (c).
(a) Strongly positive (+++) staining for FGF2 in DF. (b) Negative (-) staining for FGF2 in DFSP. (c) A colon cancer was regarded as
a positive control.
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be more relevant to the induction of epidermal
hyperplasia in the epidermal regions of DF than
FGFR2. Han K-H et al. demonstrated that the ex-
pression of EGFR is equally distributed throughout
the epidermis overlying DF, suggesting an etiologic
factor of EGF/EGFR in the induction of epidermal
hyperplasia (19). As EGFR and FGFR3 are both
transmembrane tyrosine kinase receptors (TKRs)
and are located upstream of the RAS/ a mitogen-
activated protein kinase (MAPK) pathway (20), the
activation of FGFR3 may also contribute to RAS/
MAPK pathways in the epidermal regions of DF.
Crosstalk between fibroblasts and keratinocytes
via a variety of cytokines and their receptors has
been proposed for the induction of epidermal hy-
perplasia in the epidermis overlying DF (21). There-
fore, we examined the expression of FGF1 and
FGF9, both of which are specific ligands for b iso-
form of FGFR3 (FGFR3b) expressed in epithelial
tissues, in the tumor lesions of DF (8, 16). How-
ever, we failed to detect the expression of FGF1
and FGF9 in the epidermal and dermal regions of
DF by immunohistochemical analysis. We could
not prove crosstalk between fibroblasts and kerati-
nocytes via these ligands and FGFR3.
Next, we examined the expression of FOXN1 in
the epidermal regions of DF and DFSP, and sebor-
rhoeic keratosis. Almost all normal skin samples
tested negative, and FOXN1 was localized to the
nucleus in normal epidermis samples as previously
reported (22). We also confirmed the expression
of FOXN1 in seborrhoeic keratosis as previously
reported (15), and the expression of FOXN1 was
shown to be strong in the suprabasal to granular
layer. Strong expression of FOXN1 was also ob-
served in the epidermal regions of DF, and the
expression of FOXN1 was shown to be strong in
the basal layer. On the other hand, expression was
negative (-) to weakly positive (+) in the epidermal
regions of DFSP. Although we cannot understand
the difference in the distribution of FGFR3 expres-
sion between seborrhoeic keratosis and the epider-
mal regions of DF, a positive feedback loop between
FGFR3 and FOXN1 for affecting the proliferation
and differentiation of epidermal keratinocytes must
be formed in the epidermal regions of DF as well
as seborrhoeic keratosis. Since epidermal changes
in DF must be not neoplastic but reactive, there
would be no possibility that the epidermal regions
of DF harbor somatic activating mutations of the
FGFR3 gene as we previously found in seborrhoeic
keratosis (13). Unknown mechanisms rather than
activating mutations of the FGFR3 gene or overex-
pression of ligands for FGFR3 may exist for turn-
ing on a positive feedback loop between FGFR3 and
FOXN1.
In addition to the proliferation and differentia-
tion of epidermal keratinocytes, FOXN1 has been
reported to be involved in pigmentation of the epi-
dermis (23). Hyperpigmentation in the basal layer
is generally seen in the epidermal regions of DF.
Overexpression of FOXN1 in epidermal keratino-
cytes may promote melanogenic stimulation in ad-
jacent epidermal melanocytes, inducing hyperpig-
mentation in the basal layer of the epidermal re-
gions of DF. Previously, Shishido E et al. proposed
an important role for fibroblastic tumor cell-derived
stem cell factor (SCF) in the pathogenesis of epi-
dermal hyperpigmentation in DF (24). Since SCF
derived from human fibroblasts regulates cutaneous
pigmentation, FOXN1 may have different physiologi-
cal effects from SCF.
We showed strong expressions of FGF2 and
FGFR4 in the tumor lesions of DF, while FGF2
and FGFR4 were negative in the tumor lesions of
DFSP. FGF2, which is a ligand for all four FGFRs,
has been reported to be involved in the invasion of
cancer cells and proliferation of fibroblasts around
cancer cells in an autocrine or paracrine fashion
(25). As for FGFR4, the activation of FGFR4 sig-
naling pathways has been observed in several kinds
of cancers including hepatocellular carcinomas,
breast cancers, and lung cancers (18). In addition,
activating mutations of the FGFR4 gene have also
been identified in rhabdomyosarcomas, which are
pediatric sarcomas arising from skeletal muscle
(26). Overexpression of both FGFR4 and one of its
ligand, FGF2, may contribute to the development of
the benign tumor lesions of DF through the prolif-
eration of fibroblasts in an autocrine or paracrine
fashion. The degree to which overexpression of
FGF2/FGFR4 is involved in the pathogenesis of
DF needs further investigation.
In conclusion, overexpression of FGFR3/FOXN1
in the epidermal regions of DF and FGF2/FGFR4
in the tumor lesions of DF was observed. These
expression patterns were in contrast with those of
cases of DFSP, whose diagnoses were confirmed
by the presence of the fusion transcripts of COL1A1-
PDGFB genes. The activation of FGFR signaling
pathways may be not only relevant to the pathogene-
sis of DF, but also very useful in the differential
diagnosis of DF and DFSP.
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